

| IMI  |      |           |                  |                            |
|--|------|-----------|------------------|----------------------------|
| Titre  | Type | Budget    | Date d'ouverture | Date limite                |
| <b>Appels 2018</b>   |      |           |                  |                            |
| <a href="#">IMI2-RIA: Integrated research platforms enabling patient-centric drug development</a>  | RIA  | 12 M€     | 18-juil-18       | 24/10/2018 puis 15/05/2019 |
| <a href="#">IMI2-RIA : Blockchain Enabled Healthcare</a>   | RIA  | 8,33 M€   | 18-juil-18       | 24/10/2018 puis 15/05/2019 |
| <a href="#">IMI2-RIA : Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases</a>   | RIA  | 15,5 M€   | 18-juil-18       | 24/10/2018 puis 15/05/2020 |
| <a href="#">IMI2-RIA : Emerging translational safety technologies and tools for interrogating human immuno-biology</a>   | RIA  | 11 M€     | 18-juil-18       | 24/10/2018 puis 15/05/2021 |
| <a href="#">IMI2-RIA : Development and validation of translational platforms in support of synaptopathy drug discovery</a>   | RIA  | 6 M€      | 18-juil-18       | 24/10/2018 puis 15/05/2022 |
| <a href="#">IMI2-RIA : Digital endpoints in neurodegenerative and immune-mediated diseases</a>   | RIA  | 21 M€     | 18-juil-18       | 24/10/2018 puis 15/05/2023 |
| <a href="#">IMI2-RIA : AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries</a>   | RIA  | 144,73 M€ | 18-juil-18       | 24/10/2018 puis 15/05/2024 |
| <a href="#">IMI2-RIA : AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance</a>   | RIA  | 144,73 M€ | 18-juil-18       | 24/10/2018 puis 15/05/2025 |
| <a href="#">IMI2-RIA : AMR Accelerator programme Pillar C : Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for tuberculosis (TB) that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors</a>  | RIA  | 6,84 M€   | 18-juil-18       | 24/10/2018 puis 15/05/2026 |
| <a href="#">IMI2-RIA : AMR Accelerator programme Pillar C : Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs</a>   | RIA  | 5,69 M€   | 18-juil-18       | 24/10/2018 puis 15/05/2027 |
| <a href="#">IMI2-RIA : AMR Accelerator programme Pillar C : Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection</a>  | RIA  | 1,77 M€   | 18-juil-18       | 24/10/2018 puis 15/05/2028 |
| <a href="#">IMI2-RIA : AMR Accelerator programme Pillar C : Determination of gepotidacin levels in tonsils and prostatic tissue</a>  | RIA  | 7,3 M€    | 18-juil-18       | 24/10/2018 puis 15/05/2029 |
| <a href="#">IMI2-RIA : AMR Accelerator programme Pillar C : Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections</a>   | RIA  | 6 M€      | 18-juil-18       | 24/10/2018 puis 15/05/2030 |
| <a href="#">IMI2-RIA : AMR Accelerator programme Pillar C : Functional Ethionamide boosters: a novel combination for tuberculosis therapy</a>  | RIA  | 7 M€      | 18-juil-18       | 24/10/2018 puis 15/05/2031 |
| <a href="#">IMI2-RIA : AMR Accelerator programme Pillar C : Intravenous treatments of serious infections (urinary tract infections (UTI), intra-abdominal infections (IAI) &amp; hospital-acquired pneumonia/ventilator associated pneumonia (HAP/VAP)) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)</a> | RIA  | 12,3 M€   | 18-juil-18       | 24/10/2018 puis 15/05/2032 |
| <b>Appels 2019</b>   |      |           |                  |                            |
| <a href="#">IMI2-2019-17-01: Optimising future obesity treatment</a>   | RIA  | 83,9M€    | 22-janv-19       | 25/04/2019 puis 07/11/2019 |
| <a href="#">IMI2-2019-17-02: Open access chemogenomics library and chemical probes for the druggable genome</a>  | RIA  |           | 22-janv-19       | 25/04/2019 puis 07/11/2019 |
| <a href="#">IMI2-2019-17-03: Intelligent prediction and identification of environmental risks posed by human medicinal products</a>  | RIA  |           | 22-janv-19       | 25/04/2019 puis 07/11/2019 |